Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.

Hurt AC, Ho HT, Barr I.

Expert Rev Anti Infect Ther. 2006 Oct;4(5):795-805. Review.

PMID:
17140356
2.

Anti-influenza drugs and neuraminidase inhibitors.

Roberts NA.

Prog Drug Res. 2001;56:195-237. Review.

PMID:
11417114
3.

[Research progress of neuraminidase inhibitors for anti-influenza].

Liu AL, Wang HD, Yang F, Du GH.

Yao Xue Xue Bao. 2009 Sep;44(9):935-42. Review. Chinese.

PMID:
20055166
4.

Antivirals used for influenza chemoprophylaxis.

Tsiodras S, Nikolopoulos G, Bonovas S.

Curr Med Chem. 2012;19(35):5947-56. Review.

PMID:
22963557
5.

Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

Nguyen HT, Fry AM, Gubareva LV.

Antivir Ther. 2012;17(1 Pt B):159-73. doi: 10.3851/IMP2067. Epub 2012 Feb 3. Review.

PMID:
22311680
6.

Rational development of neuraminidase inhibitor as novel anti-flu drug.

Chintakrindi A, D'souza C, Kanyalkar M.

Mini Rev Med Chem. 2012 Oct;12(12):1273-81. Review.

PMID:
22512586
7.

Antivirals for influenza: strategies for use in pediatrics.

Smith SM, Gums JG.

Paediatr Drugs. 2010 Oct 1;12(5):285-99. doi: 10.2165/11532530-000000000-00000. Review.

PMID:
20799758
8.

Anti-influenza drugs and neuraminidase inhibitors.

Roberts NA.

Prog Drug Res. 2001;Spec No:35-77. Review.

PMID:
11548210
9.

Neuraminidase inhibitors and their role in avian and pandemic influenza.

Crusat M, de Jong MD.

Antivir Ther. 2007;12(4 Pt B):593-602. Review.

PMID:
17944267
10.

Influenza virus resistance to antiviral therapy.

van der Vries E, Schutten M, Fraaij P, Boucher C, Osterhaus A.

Adv Pharmacol. 2013;67:217-46. doi: 10.1016/B978-0-12-405880-4.00006-8. Review.

PMID:
23886002
11.

A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.

Oxford J, Balasingam S, Lambkin R.

J Antimicrob Chemother. 2004 Feb;53(2):133-6. Epub 2003 Dec 19. Review.

PMID:
14688047
12.

Anti-influenza drugs: the development of sialidase inhibitors.

von Itzstein M, Thomson R.

Handb Exp Pharmacol. 2009;(189):111-54. doi: 10.1007/978-3-540-79086-0_5. Review.

PMID:
19048199
13.

Influenza drug resistance.

Pizzorno A, Abed Y, Boivin G.

Semin Respir Crit Care Med. 2011 Aug;32(4):409-22. doi: 10.1055/s-0031-1283281. Epub 2011 Aug 19. Review.

PMID:
21858746
14.

[Resistance in influenza viruses].

Hungnes O, Dudman SG.

Tidsskr Nor Laegeforen. 2008 Nov 20;128(22):2601-6. Review. Norwegian.

15.

Advances in the structure-based design of the influenza A neuraminidase inhibitors.

Mitrasinovic PM.

Curr Drug Targets. 2010 Mar;11(3):315-26. Review.

PMID:
20210756
16.

Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors.

Oxford JS, Bossuyt S, Balasingam S, Mann A, Novelli P, Lambkin R.

Clin Microbiol Infect. 2003 Jan;9(1):1-14. Review.

17.

Antivirals in the management of an influenza pandemic.

Harrod ME, Emery S, Dwyer DE.

Med J Aust. 2006 Nov 20;185(10 Suppl):S58-61. Review.

PMID:
17115954
18.

Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.

Hayden F, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J, Macken C, Hampson A, Webster RG, Amyard M, Zambon M.

Antivir Ther. 2005;10(8):873-7. Review. Erratum in: Antivir Ther. 2006;11(1):130.

PMID:
16430192
19.

Combating influenza with antiviral therapy in the pediatric population.

Townsend KA, Eiland LS.

Pharmacotherapy. 2006 Jan;26(1):95-103. Review.

PMID:
16506351
20.

Influenza.

Khare MD, Sharland M.

Expert Opin Pharmacother. 2000 Mar;1(3):367-75. Review.

PMID:
11249523

Supplemental Content

Support Center